TCIM
ALLO icon

TIAA CREF Investment Management’s Allogene Therapeutics ALLO Stock Holding History

TIAA CREF Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$6.14M Sell
212,231
-57,193
-21% -$1.66M ﹤0.01% 1311
2018
Q4 		$7.26M Buy
+269,424
New +$7.16M 0.01% 1137

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TIAA CREF Investment Management's ALLO Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Allogene Therapeutics (ALLO) stake by 21% in Q1 2019, selling an estimated $1.66M and leaving 212,231 shares worth $6.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

TIAA CREF Investment Management first reported a position in ALLO in Q4 2018 and has held it in 2 quarters since. The position peaked at $7.26M in Q4 2018. 86 funds tracked by Wall St. Rank hold ALLO as of Q1 2019.

  • TIAA CREF Investment Management held 212,231 shares of Allogene Therapeutics worth $6.14M as of Q1 2019.
  • TIAA CREF Investment Management sold 57,193 Allogene Therapeutics shares in Q1 2019, an estimated $1.66M.
  • Allogene Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1311 holding.
  • TIAA CREF Investment Management first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 2 quarters since.
  • TIAA CREF Investment Management's Allogene Therapeutics position peaked at $7.26M in Q4 2018.
  • 86 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.